ANZEMET Drug Patent Profile

When do Anzemet patents expire, and what generic alternatives are available?

Anzemet is a drug marketed by Validus Pharms and is included in two NDAs.

The generic ingredient in ANZEMET is dolasetron mesylate. There are five drug master file entries for this compound. Additional details are available on the dolasetron mesylate profile page.

Summary for ANZEMET

US Patents:	0
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for ANZEMET

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Validus Pharms	ANZEMET	dolasetron mesylate	INJECTABLE;INJECTION	020624-002	Sep 11, 1997		DISCN	Yes	No
Validus Pharms	ANZEMET	dolasetron mesylate	TABLET;ORAL	020623-001	Sep 11, 1997		DISCN	Yes	No
Validus Pharms	ANZEMET	dolasetron mesylate	INJECTABLE;INJECTION	020624-001	Sep 11, 1997		DISCN	Yes	No
Validus Pharms	ANZEMET	dolasetron mesylate	INJECTABLE;INJECTION	020624-003	Dec 11, 2001		DISCN	No	No
Validus Pharms	ANZEMET	dolasetron mesylate	TABLET;ORAL	020623-002	Sep 11, 1997		DISCN	Yes	No

International Patents for ANZEMET

See the table below for patents covering ANZEMET around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	90082
Australia	600318
Hungary	T50172
Finland	891954
Japan	S63258476	ESTERS OF HEXAHYDRO-8-HYDROXY-2, 6-METHANO-2H- QUINOLIDIN-3(4H)-ONE AND RELATED COMPOUNDS

Supplementary Protection Certificates for ANZEMET

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0266730	98C0014	Belgium		PRODUCT NAME: MIGLITOL; NAT. REGISTRATION NO/DATE: NL 22 138 19970204; FIRST REGISTRATION: NL - 19 343 UR 19960723
0266730	C970043	Netherlands		PRODUCT NAME: DOLASETRON, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZUURADDITIEZOUT, IN HET BIJZONDER HET MESYLAAT; NAT REGISTRATION NO/DATE: RVG 21707 - RVG 21709 19970623; FIRST REGISTRATION: GB PL 04425/0150, PL 04425/0152, PL 04425/0154 19960926
0266730	73/1997	Austria		PRODUCT NAME: ANZEMET; NAT. REGISTRATION NO/DATE: 1-22014, 1-22015, 1-22016 19970624; FIRST REGISTRATION: GB PL 04425/0150 19960926
0266730	SPC/GB97/005	United Kingdom		PRODUCT NAME: DOLASETRON, OR A PHARMACEUTICALLY-ACCEPTABLE ACID ADDITION OR QUATERNARY AMMONIUM SALT THEREOF; REGISTERED: UK 04425/0150 19960926

Last updated: April 25, 2026

ANZEMET (dolasetron): Investment scenario and fundamentals analysis

Bottom line: ANZEMET (dolasetron) is a niche, late-life injectable/oral antiemetic franchise with value anchored to existing formularies and steady, low-growth demand. Fundamentals skew toward defensive cashflow rather than scale-up upside, with meaningful risk from generic competition, margin compression, and weak pipeline substitution for the core asset.

---

What is ANZEMET and how is it positioned commercially?

ANZEMET is an antiemetic that uses dolasetron (a 5-HT3 receptor antagonist). In practice, it is used to prevent/treat nausea and vomiting associated with surgery and chemotherapy settings (label use is route and indication dependent by market).

From an investment lens, the commercial profile fits a mature “off-patent brand” pattern:

• Low innovation velocity (no new platform differentiation)
• Demand tied to entrenched clinical practice (perioperative and chemotherapy supportive care)
• Pricing and mix under pressure from generics
• Limited “brand premium” retention outside specific procurement dynamics

---

What patents and exclusivity still matter for value?

ANZEMET’s patent posture has largely transitioned to the generics era. The key investment implication is that brand-level pricing power is time-compressed once exclusivity lapses and generics become widely available.

Patent and regulatory reality check (investment framing)

A mature small-molecule antiemetic typically has:

• Early composition-of-matter expiry
• Expired or near-expired use/formulation coverage
• Potentially minimal incremental value from later lifecycle patents once generic entry occurs

For ANZEMET, this translates into:

• Low expectation of new exclusivity-driven profit expansion
• Valuation sensitivity to generic penetration and tender outcomes
• Higher likelihood of ongoing share loss rather than share gain

---

What do fundamentals say about demand durability and volume drivers?

Demand drivers (supportive care basics)

ANZEMET demand is pulled by:

• Hospital surgical volumes (perioperative nausea and vomiting prophylaxis)
• Oncology supportive care pathways (regimens that include 5-HT3 antagonists or alternatives)
• Formulary inclusion and substitution rules in hospital systems
• Switching costs: once a formulary locks in a class of 5-HT3 agents, switching depends on clinical protocols and procurement

Demand risks

• Therapy substitution within class: hospitals can rotate between 5-HT3 antagonists based on price, supply, and formulary policies.
• Protocol evolution: newer supportive-care combinations can reduce reliance on any single agent.
• Generic interchangeability: buyers favor the lowest-cost equivalent.

Growth outlook

For a late-life antiemetic brand, the base case is:

• Stable to declining unit volumes
• Flat to down net pricing as tendering and generic penetration continue
• Net sales growth near zero absent new coverage or supply constraints

---

How does the competitive landscape affect margins and pricing?

Competitive set dynamics

ANZEMET competes in the 5-HT3 antiemetic class and in broader antiemetic pathways. In mature supportive care markets:

• Generic 5-HT3 agents usually trade at a discount to the branded product
• Procurement often shifts by tender price and contract terms
• Brand retention depends on specific tender contracts, reimbursement idiosyncrasies, or hospital-specific practice patterns

Margin implication

For investors, the key margin story is:

• Gross margin compression driven by price competition
• Higher promotional and channel spend needed to hold share
• Lower operating leverage if volume declines

---

What are the key regulatory and safety considerations investors price in?

Dolasetron as a 5-HT3 antagonist carries class-related clinical monitoring themes. For investment decisioning, safety affects:

• Label usage restrictions
• Hospital protocol adoption
• Liability risk costs and potential withdrawal events (rare but priceable as tail risk)

In mature products, the market usually has already priced major historical safety signals into prescribing behavior and procurement policies, which supports a “known-risk” valuation approach rather than a “surprise-risk” approach.

---

What does the investment scenario look like under three market cases?

Case 1: Base case (contract-by-contract retention)

Assumptions:

• Ongoing generic competition caps price
• Formularies remain partially favorable
• Unit volumes drift down slowly

Investment impact:

• Cash generation remains positive but limited
• Valuation is driven by net revenue durability, not growth

Case 2: Downside (accelerated tender-driven share loss)

Assumptions:

• Competitive tender resets shift to generics
• Substitution within class increases
• Net pricing declines faster than volume

Investment impact:

• Operating leverage turns negative
• Asset value compresses via discounted cashflow deterioration

Case 3: Upside (supply or formulary inertia supports defensible share)

Assumptions:

• Supply stability and procurement frictions reduce substitution
• A subset of hospitals retains protocols favoring the brand
• Mix improves modestly toward higher utilization settings

Investment impact:

• Slower decline than expected supports multiple stabilization
• Upside is capped by generic economics

---

What is the valuation thesis: where does the money come from?

For ANZEMET, the investable thesis typically has these pillars:

• Defensive cashflow from existing prescriptions and hospital inertia
• Cost discipline in manufacturing and commercialization
• Lower R&D intensity relative to pipeline-led biopharma models (if the investment vehicle is an off-patent brand holder or royalty stream)
• Contract and tender management as the main operational lever

Practical valuation drivers

• Current and trend net pricing versus generic parity
• Hospital formulary retention rate
• Distribution coverage and wholesaler fill reliability
• Compliance and pharmacovigilance cost trajectory
• Any residual litigation or exclusivity tail (if present) that delays generic substitution

---

What are the key diligence questions that map directly to returns?

Investment-grade diligence should focus on measurable items:

• Share and net revenue trend by channel (hospital, retail, specialty)
• Generic substitution timing and contract expiry cadence
• Gross-to-net bridge: rebates, chargebacks, and wholesaler terms
• Regional formulary penetration and switching history
• Inventory and supply chain continuity (any chronic interruptions reduce retention)
• Safety communications impact: whether restrictions broaden or tighten

---

Key Takeaways

1. ANZEMET is a mature antiemetic franchise where investment returns depend on defensive net revenue durability, not growth.
2. Generic competition and tender economics are the dominant forces shaping pricing, share, and margin.
3. The scenario set is best modeled as cashflow protection vs. accelerated share loss, with limited upside due to late lifecycle stage.
4. Diligence should prioritize net revenue bridge, formulary retention, and contract timing over long-horizon therapeutic innovation narratives.

---

FAQs

1. Is ANZEMET still patent-protected in a way that supports brand premium pricing?
   The investment reality is that ANZEMET’s value largely reflects late-life brand retention under generic pressure rather than a fresh exclusivity-driven premium.

2. What drives hospital demand for ANZEMET in supportive care?
   Hospital surgical volumes, chemotherapy supportive care protocols, and formulary inclusion determine utilization more than standalone patient demand.

3. How does generic competition usually affect 5-HT3 antiemetic brands?
   It compresses net pricing and increases substitution, typically producing stable or declining volume with margin pressure.

4. What operational lever matters most for downside protection?
   Tender and contract management that preserves formulary position and limits rapid switch to lower-cost equivalents.

5. What is the most important investor risk for a mature antiemetic?
   Faster-than-expected share loss driven by procurement resets and broader within-class substitution.

---

References

[1] FDA. Drug Approval Package: ANZEMET (dolasetron). U.S. Food and Drug Administration.
[2] DailyMed. ANZEMET (dolasetron) prescribing information. U.S. National Library of Medicine.